U.S. IVD Market by Product Type - Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4403091
  • Report
  • Region: United States
  • 140 pages
  • Allied Analytics LLP
1 of 3
In vitro diagnostics (IVD) is the diagnostic solution used by patients for detection of various diseases such as infections, cancer, cardiovascular immunological, nephrological, and gastroenterological diseases in an in vitro environment. The continuous need for diagnosis and treatment of different diseases has makes way for the need of numerous technological advancements in the IVD market. These advancements continue in future as well to identify new diseases, improve living standards, and provide healthcare access to the patients. IVD testing is performed by using reagents, analytical instruments, and accessory products.

Increase in infectious and chronic diseases and rise in geriatric population drive the market. In addition, demand for personalized medicines and technological advancements to improve efficacy of IVD, rise in disposable income, and high healthcare expenditure are expected to fuel the market growth. Furthermore, increase in awareness of preventive diagnosis & treatment among the population is anticipated to increase the market growth during the forecast period. However, stringent government rules and regulations are expected to hinder the growth of this market. Ongoing R&D is anticipated to present new opportunities for the market. The U.S. IVD market is accounted for $15,746 million in 2016, and is estimated to reach at $20,707 million by 2023, growing at a CAGR of 3.9% from 2017 to 2023.

The market is segmented on the basis of product type, techniques, application, and end user. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is divided into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point of care testing, and others.

KEY BENEFITS FOR SHAREHOLDERS

The study provides an in-depth analysis of the U.S. IVD market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis from 2016 to 2023, which enables stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product Type

Reagents
Instruments
Software and Services

By Techniques

Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications

By End Users

Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others

List of players profiled in the report

Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
READ MORE
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 PORTERS FIVE FORCES ANALYSIS

3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry

3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS

3.5.1 Drivers

3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach

3.5.2 Restraint

3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies

3.5.3 Opportunity

3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies

CHAPTER 4 IVD MARKET, BY PRODUCT TYPE

4.1 OVERVIEW

4.1.1 Market size and forecast

4.2 REAGENTS

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 INSTRUMENTS

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 SOFTWARE AND SERVICES

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

CHAPTER 5 IVD MARKET, BY TECHNIQUE

5.1 OVERVIEW

5.1.1 Market size and forecast

5.2 IMMUNODIAGNOSTICS

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)

5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)

5.2.4.2.1 Market size and forecast

5.2.4.3 Fluorescence immunoassay (FIA)

5.2.4.3.1 Market size and forecast

5.2.4.4 Colorimetric immunoassay (CI)

5.2.4.4.1 Market size and forecast

5.2.5 Rapid tests

5.2.5.1 Market size and forecast

5.2.6 Enzyme-linked immunospot (ELISPOT)

5.2.6.1 Market size and forecast

5.2.7 Radioimmunoassay (RIA)

5.2.7.1 Market size and forecast

5.2.8 Western blot

5.2.8.1 Market size and forecast

5.3 BLOOD TESTING

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 MOLECULAR DIAGNOSTICS

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)

5.4.4.1 Market size and forecast

5.4.5 Isothermal nucleic acid technology (INAAT)

5.4.5.1 Market size and forecast

5.4.6 Hybridization

5.4.6.1 Market size and forecast

5.4.7 DNA diagnostics

5.4.7.1 Market size and forecast

5.4.8 Microarray

5.4.8.1 Market size and forecast

5.4.9 Others

5.4.9.1 Market size and forecast

5.5 TISSUE DIAGNOSTICS

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

5.6 CLINICAL CHEMISTRY

5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel

5.6.4.1 Market size and forecast

5.6.5 Liver panel

5.6.5.1 Market size and forecast

5.6.6 Renal profile

5.6.6.1 Market size and forecast

5.6.7 Lipid profile

5.6.7.1 Market size and forecast

5.6.8 Thyroid function panel

5.6.8.1 Market size and forecast

5.6.9 Electrolyte panel

5.6.9.1 Market size and forecast

5.6.10 Speciality chemicals

5.6.10.1 Market size and forecast

5.7 OTHER IVD TECHNIQUES

5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast

CHAPTER 6 IVD MARKET, BY APPLICATION

6.1 INFECTIOUS DISEASES

6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast

6.2 CANCER

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast

6.3 CARDIAC DISEASES

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast

6.4 IMMUNE SYSTEM DISORDERS

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast

6.5 NEPHROLOGICAL DISEASES

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast

6.6 GASTROINTESTINAL DISEASES

6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast

6.7 OTHERS INDICATIONS

6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast

CHAPTER 7 IVD MARKET BY END USERS

7.1 STANDALONE LABORATORIES

7.1.1 Market size and forecast

7.2 HOSPITALS

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast

7.3 ACADEMIC AND MEDICAL SCHOOLS

7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast

7.4 POINT OF CARE TESTING

7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast

7.5 OTHERS END-USER

7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1 THERMO FISHER SCIENTIFIC INC.

8.1.1 Company overview
8.1.2 Business performance
8.1.3 Key strategies and development

8.2 ALERE INC.

8.2.1 Company overview
8.2.2 Business performance
8.2.3 Key strategies and developments

8.3 BIOMERIEUX

8.3.1 Company overview
8.3.2 Business performance
8.3.3 Key strategies and developments

8.4 DANAHER CORPORATION

8.4.1 Company overview
8.4.2 Business performance
8.4.3 Key strategies and development

8.5 F. HOFFMANN-LA ROCHE AG

8.5.1 Company overview
8.5.2 Business performance
8.5.3 Key strategies and developments

8.6 BECTON DICKINSON AND COMPANY

8.6.1 Company overview
8.6.2 Business performance
8.6.3 Key strategies and development

8.7 BIO-RAD LABORATORIES

8.7.1 Company overview
8.7.2 Business performance
8.7.3 Key strategies and developments

8.8 BAYER AG

8.8.1 Company overview
8.8.2 Business performance
8.8.3 Key strategies and development

8.8 SYSMEX CORPORATION

8.8.1 Company overview
8.8.2 Business performance
8.8.3 Key strategies and developments

8.10 JOHNSON & JOHNSON

8.10.1 Company overview
8.10.2 Business performance
8.10.3 Key strategies and development
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll